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Brazilian experience using high-dose sequential therapy (HDS)
followed by autologous hematopoietic stem cell transplantation (ASCT) for
malignant lymphomas
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Using the overall survival (OS), disease free survival (DFS) and progression free
survival (PFS), as well as associated toxicity, the purpose of this work was to evaluate
the effectiveness of HDS followed by ASCT as salvage therapy. A retrospective analysis
was performed of 106 patients with high grade non-Hodgkin lymphoma receiving
HDS followed by ASCT, between 1998 and 2006. Median age was 45 years (Range:
8-65), with 66 (62%) men. Histopathological classification was: 78% DLBCL patients,
12% T and anaplastic and 9% Mantle cell lymphomas; 87% had B cell and 12% T
cell lymphomas; 83% were stage III-IV (Ann Arbor Staging), 63% had B symptoms,
32% had bone marrow involvement, 62% bulky disease and 42% high-intermediate
or high risk IPI. After HDCY, 9 patients died, 7 from toxicity and 2 from sepsis. Eighty
patients underwent ASCT, 47% were in complete remission (CR) and 15% died, all
from toxicity. Their OS was 45% over 8 years. During the follow-up, another 35
patients died [4 CR, 1 partial response (PR), 2 relapsed disease (RD) and 28 disease
progression (DP)], 11 (31%) had not performed ASCT. OS was 37%; DFS was 49%
and PFS 28%. OS by diagnosis was 42% for DLBCL, 40% for T-cell (8 y) and 20%
for Mantle Cell (6 y) (P=NS). OS by B symptom patients was 22% vs. 58% (P=0.002)
and PFS was 23% vs. 37% (P=0.03). Patients who achieved CR after HDCY (38)
had significantly better OS and PFS (38% and 17%) than patients who remained in
DP (P<0.0001). Cox Regression demonstrated therapeutic lines before HDCY
(Relative risk - RR = 1.41; CI 95%: 1.04-1.90; P= 0.02) and PD both before (RR =
2.70; CI 95%: 1.49-4.91, P<0.001) and after HDCY (RR = 5.38; 95% CI: 2.93-9.87;
P<0.0001). Conclusions: Our study suggests HDS is an efficient treatment to improve
status and to reduce tumoral burden. Regardless of toxicity-related mortality it is
feasible, especially considering the poor prognosis of patients. Rev. Bras. Hematol.
Hemoter. 2009;31(Supl. 2):9-14.
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Introduction
A dose intensified regimen, such as high dose sequential
therapy (HDS) followed by autologous hematopoietic stem
cell transplantation (ASCT) is an effective and feasible salvage
therapy for resistant and relapsed malignant lymphomas.1,2,3-8
It consists of an intensified debulking phase by sequential
administration of high-dose cyclophosphamide (HDCY)
followed by high-dose methotrexate (HDMTX), (only for
Hodgkin's lymphoma - HL) and high-dose etoposide (HDVP),
peripheral blood progenitor cell (PBPC) harvesting, HDS and
ASCT.9
Despite proof of its efficacy reported by several
investigators for both HL10-12 and non-Hodgkin's lymphoma
(NHL), 13-15 there are few studies using this strategy in Brazil
and few groups around the world evaluated the use of this
therapy with over 5-year follow-up periods. Our aim was to
evaluate the effectiveness and toxicity of HDS used as salvage
therapy for malignant lymphomas, focusing on overall survival
(OS), disease free survival (DFS) and progression-free survival
(PFS).
Patients and Method
Seventy-seven patients diagnosed with relapsed or
refractory HL and 106 patients with high grade NHL were treated
with HDS between 1998 and 2006 in three different institutions:
University of Campinas, Vera Cruz Hospital and the Boldrini
Children's Cancer Center. Data was obtained from the patients'
medical records. Eligibility criteria included failure to achieve
complete remission (CR) after first-line treatment (non-
responsive, NR), relapsed disease even when in CR before
mobilization, and adequate psychiatric conditions to
participate. All patients or their legal representatives provided
written, informed consent before receiving this regimen.
Treatment procedures were approved by the Research Ethics
Committee of each participating institution, according to the
principles of the Helsinki Declaration.
Treatment procedures and definitions
HDS consisted of the sequential administration of HDCY
(4 or 7g/m2) and G-CSF (300 µg/day, from day +1 after HDCY),
followed by PBPC harvesting when white blood cells increased
to > 1.0 x 109/L, with the aim of collecting > 5x106 CD34+ cells/
kg. G-CSF was stopped after the last day of apheresis. Patients
with an insufficient number of CD34+ cells underwent another
collection after etoposide. In some cases where peripheral cells
could not be harvested, harvesting was made directly from the
bone marrow. After PBPC harvesting, methotrexate (8g/m2) plus
vincristine (1.4mg/m2) (only in patients with HL) and etoposide
(2g/m2) were administered.
Disease status was assessed preferably before HDCY,
before ASCT, after ASCT and throughout the long-term follow-
up (every three months in the first year, every six months in the
second year and annually thereafter).
Data collection and statistical analysis
Analysis was based on data available in February 2009.
OS was calculated from HDCY date until the date of death or
last follow-up. DFS included only patients who achieved CR
and was calculated from the date of CR assessment until the
date of relapse, last follow-up or death. PFS included all patients
and was calculated from HDCY date until the date of
progression, relapse, last follow-up or death due to any cause.
Actuarial curves of OS, DFS and PFS were analyzed using the
Kaplan-Meier method and compared by the log-rank test.
Multivariate predictors of outcome (OS, DFS and PFS) were
assessed by Cox regression analysis, using the forward




The median age was 23 years (Range: 7-68) at
diagnosis, with 46/77 (60%) men. Histopathological
diagnosis16 was: 65% nodular sclerosis, 25% mixed
cellularity, 6% lymphocyte depleted, 1.5% lymphocyte
predominant and 2.5% patients unknown. Stage III-IV17 was
65%, 71% had B symptoms, 14% had bone marrow
involvement and 40% had bulky disease (≥  10 cm). Before
HDCY, patients were treated with a median of two therapeutic
lines, including conventional chemotherapy and
radiotherapy. Three patients were in CR after treatment with
conventional therapy for relapsed disease and 54.5% were
in disease progression (DP) before mobilization with HDCY.
Mobilization, PBPC harvesting and toxicity
CY was administered after a median time of 1.5 years
from diagnosis. Thirty patients (39%) received a dose of 4g/m2
due to advanced age (> 65 years) or borderline cardiac function,
and 47 patients (61%) received 7g/m2. The latter group had
more patients in DP (57% vs. 50%; p = 0.02) and more patients
with B symptoms (80% vs. 57%; p = 0.02). The 4g/m2 group
had a greater prevalence of previous use of radiotherapy (73%
vs. 44%; p = 0.01). There were no significant differences in the
other parameters.
The median day of leukapheresis after HDCY was +13
(Range: 8-27), with a median of three sessions (Range: 1-8)
and a median number of harvested CD34+ cells of 5.98 x 106
cells/kg (Range: 0.23-45.01 x 106).
Twenty-one patients (27%) died after HDCY. Six died
from toxicity, nine from DP, four from sepsis while in DP and
insufficient cells were harvested from one; this patient
developed myelodisplastic syndrome (MDS) and died from
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sepsis while in CR. Moreover, one case died 16 months after
HDS from refractory congestive heart failure, giving a total of 7/
77 (9%) patients with HDS-related mortality. Besides these
patients, three more were not submitted to ASCT, thus 24 patients
(31%) did not undergo ASCT.
We obtained data on toxicity for 71 patients. Sixty-six
patients (93%) presented with hematologic toxicity. Forty patients
experienced gastrointestinal toxicity, nine patients from cardiac
toxicity, six patients from asymptomatic reduction of the ejection
fraction, one patient from cardiac failure and another one died
with severe heart failure. Seven patients developed acute renal
failure not related to sepsis. Finally, 19 patients had fever of
unknown origin.
Autografting
Autografting was performed in 53 patients with a median
of 118 days after HDCY (Range: 62-407). BEAM was used as a
conditioning regimen in 81%. The median times for granulocyte
(>0.5x109/L) and platelet (>20 x 109/L) engraftment were 11 days
(Range: 9-27) and 17 days (Range: 6-88), respectively. Auto-
engraftment related mortality was 6%. OS for transplanted
patients was 46% over five years. Twenty-nine patients died
after ASCT as described in the long-term outcome.
Long-term outcome
Of the 77 patients who were submitted to HDCY, 21 died
before ASCT. Another three patients did not undergo ASCT. A
total of 53 patients were submitted to ASCT and until now 45%
are alive. Twenty-nine patients died after ASCT. Another patient
developed MDS and is alive, totaling four patients (5%) who
developed AML/MDS.
A total of 27 patients are alive for a median of 66 months
after HDCY (Range: 3-128). Eighteen patients are in CR for a
median of 70 months after HDCY (Range: 17-128).
OS was 27% with a median time of 18 months (Range: 0.1-
128); DFS was 57% with a median of 45 months (Range: 1.5-125);
PFS was 25% with a median 13 months (Range: 0.1-128).
We analyzed the survival of patients initially in DP (57/77
- 74%) according to their disease status before HDCY. Patients
who achieved CR after HDCY (24/57 - 42%) had a significantly
better OS and PFS (36%-33%) than patients who remained in DP
(10%-17%). We also analyzed the survival of patients according
to HDCY dose, for which no significant difference was found.
Additionally we analyzed survival data based on age, stage
and histopathological and laboratory findings at diagnosis and
found no significant differences.
For the multivariate analysis two variables remained: LDH
(as categorical variable - Hazard ratio - HR = 2.41; 95% CI: 1.04-
5.59; P = 0.04) and DP after HDCY (HR = 3.97; 95% CI: 1.73-9.10;
P = 0.001). In summary, 65% patients died; 46% from DP, 26%
from sepsis, 14% had HDS-related deaths, 6% had ASCT-related
deaths, 6% had AML/MDS and 2% had extensive chronic graft-
verses-host disease (GVHD) due to a reduced intensity
conditioning (RIC) allogeneic transplantation.
Non-Hodgkin Lymphoma
Patients' characteristics
One hundred and six patients were enrolled with a
median age of 45 years (Range: 8-65), with 66 men.
Histopathological classification16 was: 78% diffuse large B-
cell lymphoma (DLBCL), 12% T and anaplastic lymphoma
and 10% mantle cell lymphoma. At diagnosis, 83% were in
stage III-IV,17 63% had B symptoms, 32% had bone marrow
involvement, 62% bulky disease and 42% had high-
intermediate or high risk IPI 18.
Before HDCY, patients were treated with a median of
one therapeutic line, including conventional chemotherapy
and radiotherapy. Six patients were in CR after their first relapse
after treatment with conventional chemotherapy and 38 were
in partial response (PR). More than half were in DP or
refractory relapsed disease.
Mobilization, PBPC harvesting and toxicity
CY was administered after a median time of 10 months
after diagnosis. Forty-two patients received a dose of 4g/
m2 and 64 patients received 7g/m2. Groups differed
statistically according to IPI (66% - 4 g/m2 vs. 30% -7 g/m2;
p = 0.006) and in prevalence of altered serum LDH (68% -
4 g/m2 vs. 41% - 7 g/m2; p < 0.0001).
The median leukapheresis day after the HDCY was
+13 (Range: 3-83), with a median of two sessions (Range: 1-
7) and a median number of harvested CD34+ cells of 6.74 x
106 cells/kg (Range: 1.29-44.01 x106).
Eighteen patients (17%) died after HDCY. As well as
these patients, 8 did not undergo ASCT, totaling 26 patients
(24.5%) who were not submitted to ASCT.
We were able to recover toxicity data for 102 (96%)
patients. All patients presented hematologic toxicity. Forty-
seven patients experienced gastrointestinal toxicity, ten
cardiac toxicity, six asymptomatic reduction of the ejection
fraction, two heart failures, one severe pleural effusion and
one died due to severe congestive heart failure. Four
patients presented acute renal failure that was not due to
sepsis. Finally, 27 (25.5%) patients presented fever of
unknown origin.
Autografting
ASCT was performed in 80 patients after a median of
123 days (Range: 45-1710) from HDCY. BEAM was used as
a conditioning regimen in 87. The median time for
granulocyte engraftment (neutrophil count > 0.5x109/L) was
11 days (Range: 6-29) and 16 days (Range: 5-70) for platelet
engraftment (platelet count >20x109/L). Auto-engraftment
related to mortality was 14%. Twenty-six patients did not
autograft.
Only five patients who were not submitted to ASCT
are alive: 1 DP, 2 CR and 2 PR. OS for patients submitted to
ASCT was 45% over eight years.
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Long-term outcome
Twenty-six patients did not undergo ASCT: 18 died prior
to the procedure and eight patients were not transplanted for
other reasons, with six of them still alive. Another 37 patients
died during follow-up, 11 due to ASCT toxicity, 12 due to DP,
13 from sepsis and one from chronic GVHD after being
submitted to a RIC allogeneic transplantation. One patient
developed MDS and remains alive.
Until the closing date of this analysis, 49/106 patients
are alive, with a median of 68 months. OS was 41% with a
median of 30 months (Range: 0.2-124), DFS was 49% with a
median of 36 months (Range: 1.5-118) and PFS was 31% with
a median of 16 months (Range: 0.2-124).
We observed better OS (60 and 40%) and PFS (27 and
24%) for patients without B symptoms at diagnosis (p=0.03
and p=0.02, respectively). Patients who achieved CR after
HDCY (38) had significantly better OS and PFS (44%-27%)
compared to patients who remained in DP (24 patients with
0% and 0%)
OS, PFS and DFS were not affected by the CY dose. We
also analyzed the outcome of patients based on age, stage,
histopathological findings at diagnosis and IPI and found no
significant differences.
From the variables included in univariate analysis, DP
before (HR = 2.56; CI 95%: 1.42-4.62; p < 0.001) and after (HR
= 5.52; CI 95%: 3.01-10.1; p < 0.001) HDCY were associated
with worse OS.
On multivariate analysis, the results were: presence of B
symptoms, LDH, and DP or relapse before HDCY for OS,
whereas for PFS, B symptoms and DP or relapse before HDCY
remained.
Overall, mortality was 57/106 (54%); causes were 42%
DP, 12% related to HDCY, 19% related to ASCT, 23% infections,
2% from chronic GVHD after being submitted to a RIC
allogeneic transplantation and 2% from an unknown cause. In
addition, one patient developed MDS and remains alive.
Discussion
The intention of analyzing a Brazilian cohort has several
implications because the frequency of some important poor
prognostic factors, such as B symptoms and bulky disease,
are higher in our patients compared to series from the Northern
Hemisphere.19-21 In an Italian study22 evaluating HDS in 102
patients with refractory or recurrent HL, 42% had B symptoms
and 29% had bulky disease. In another study23 evaluating the
use of HDS and ASCT in 494 Spanish patients with refractory
or recurrent HL, 40.5% had B symptoms and 33% had bulky
disease. These numbers contrast with the 71% of patients
with B symptoms and the 40% of patients with bulky disease
seen in our patients with HL. The same is true with NHL
patients.
The higher prevalence of such variables in our
population indicates that they are probably expected to have
poorer results when compared to other populations in
developed countries.
Another possible factor contributing to a worse
outcome in our patients is a high prevalence of Epstein-Barr
virus-associated (EBV-associated) HL, although we did not
collect this information. Despite the controversy surrounding
the possible influence of EBV on the outcome of HL, a few
studies suggest that OS is worse when EBV is present in
adult patients.24 While the prevalence of EBV in developed
countries is around 30%,24 one study performed at our
institution showed a prevalence of 64%.20 This difference
may be due to low socioeconomic status (as we are a
governmental institution which provides care for low income
patients) and not due to ethnic differences between our
population and those from developed countries. A lower
income leads to a delay in diagnosis.
The higher prevalence of worse prognostic factors in
our population is reflected by the poor OS and PFS of HL
patients (27% and 25%) when compared to other studies,
with OS and PFS ranging from 50%-65%.22,25-27 However, this
was not observed for NHL patients, with OS of 41% and a
PFS of 31%, similar to those observed by other authors, where
OS ranged from 40%-45%.13-15,27,28
This difference in response between HL and NHL
patients has not been previously reported. Although the
greater prevalence of high-risk patients can justify the worse
survival observed in our HL patients, it should have also
impacted survival of NHL patients. This finding, in a
population of similar social-demographic conditions, with
high-risk, advanced disease treated under the same protocol
and within the same institution shows the need of a better
understanding of the differences between the response of
HL and NHL to HDS.
These data should point to a review of HDCY use in HL,
usually a more benign disease, where patients could benefit
from less intensive regimens. The lower number of studies
evaluating HDS in HL than in NHL only reinforces the need for
such a review.
However, the use of different doses, and sometimes
drugs, between our study and others should be highlighted
as a factor which could justify the differences mentioned
above.
We did not expect the lack of benefit of using a higher
dose regimen in both HL and NHL. We employed at our
institution a 7g/m2 dose of HDCY and a less intense one of
4g/m2 based on findings of the Italian group.28 This was
developed based on the Norton-Simon hypothesis29 that we
should seek a treatment regimen that employs the highest
possible dosing, over the minimum period of time, with
acceptable toxicity. By showing no extra benefit, neither in
OS nor in response rates, of the higher dose regimen, our
study suggests that its benefit was exceeded by its toxicity,
resulting in a similar survival rate, when compared to a less
dose-intense regimen.
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Even though the 7 g/m2 regimen did not improve survival,
the role of a high-dose debulking regimen is highlighted by
the observation that patients previously in DP, who responded
to HDCY and achieved CR, had a better overall survival. This
not only shows the ability of HDCY to overcome primary
chemo-resistance in a significant proportion of refractory
patients, but also its importance in assessing malignant
lymphoma chemo-sensitivity, since there was no benefit in
submitting patients to HDS and ASCT when they did not
respond to HDCY.
Nevertheless, this high-dose debulking regimen imposed
a high toxicity burden, with HDCY-related mortality of 6.6% for
NHL and 7.8% for HL, which is slightly worse than the 5% rate
observed elsewhere, 28 but still acceptable.
One point that should be noted is the incidence of
secondary hematological malignancy, especially in HL
patients. We know today that death due to second cancers is
now the most common cause of mortality among long-term
survivors of HL.30 The incidence of secondary hematological
malignancy for HL in our study was 5.2%. This rate appears
to be similar to those observed in other studies,31,32 and
although credited to the cytotoxic effects of alkylating agents,
the role of cytogenetic instability related to the disease and
ASCT has yet to be determined, especially when we consider
the significantly lower incidence of this complication in
patients with NHL in our study (0.9%) treated under the same
regimen.
Our study has some limitations typical of retrospective
studies. However, we can conclude that despite the significant
number of toxicity-related deaths, our data suggest that this
regimen is feasible, especially for chemo-sensitive patients.
The development of secondary neoplasias is a special
concern in this setting, particularly for HL patients.
Resumo
A proposta deste trabalho foi avaliar a eficácia da HDS seguida
do transplante autólogo como terapia de salvamento através da
sobrevida global, livre de doença e livre de progressão bem como
sua toxicidade. Realizou-se estudo retrospectivo com 106 pacientes
com LNH de alto grau de malignidade entre 1998 e 2006. A
mediana de idade foi 45 anos (8-65); 62% homens; DLBCL, 78%;
12%, T e anaplásico e 9%, linfoma da zona do manto; 87%,
células B; 83% estádios III-IV; 63% com sintomas B; 32% com
infiltração da medula óssea ao diagnóstico; 62% com grande
massa e 42% com IPI de alto risco ou intermediário. Após alta
dose de ciclofosfamida (HDCY), nove pacientes faleceram. Oitenta
pacientes realizaram o transplante, sendo que 47% estavam em
RC e 15% faleceram devido à toxicidade. A sobrevida global foi
de 45% em oito anos para estes pacientes. Trinta e cinco pacientes
não realizaram o transplante por causas diversas. Sobrevida
global para todos os pacientes foi de 42%, DLBCL, 40%; T-cell,
40% e zona do manto, 20% (P=NS). Pacientes que obtiveram RC
após HDCY tiveram melhor sobrevida global e livre de progressão
(38% e 17%, respectivamente) do que os que permaneceram em
PD (P<0.0001). O modelo de Cox resultou que o número de linhas
terapêuticas antes da HDCY (RR 1.41 IC 95%: 1.04-1.90, P=0.02)
e PD antes da HDCY (RR 2.70, IC 95%: 1.49-4.91, P<0.001) e
após HDCY (RR 5.38, IC 95%: 2.93-9.87, P<0.0001). Nosso
estudo sugere que HDS é um método eficiente de tratamento para
melhorar o status e reduzir a massa tumoral. Em relação à
toxicidade, é factível, especialmente em pacientes de prognóstico
ruim Rev. Bras. Hematol. Hemoter. 2009;31(Supl. 2):9-14
Palavras-chave: Linfomas malignos; terapia sequencial de alta
dose; transplante autólogo; experiência brasileira.
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